161 related articles for article (PubMed ID: 30179888)
1. nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin.
Saad AG; Grada Z; Bishop B; Abulsayen H; Hassan M; Firpo-Betancourt A; Teruya-Feldstein J; Fraig M; El Jamal SM
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):644-648. PubMed ID: 30179888
[TBL] [Abstract][Full Text] [Related]
2. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
3. Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.
Veldman-Jones MH; Lai Z; Wappett M; Harbron CG; Barrett JC; Harrington EA; Thress KS
Clin Cancer Res; 2015 May; 21(10):2367-78. PubMed ID: 25301847
[TBL] [Abstract][Full Text] [Related]
4. Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia.
Phang KC; Akhter A; Tizen NMS; Rahman FA; Zahratul Azma R; Elyamany G; Shabani-Rad MT; Masir N; Mansoor A
J Clin Pathol; 2018 Mar; 71(3):215-220. PubMed ID: 28775174
[TBL] [Abstract][Full Text] [Related]
5. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN
Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
8. Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues.
Yan WH; Jiang XN; Wang WG; Sun YF; Wo YX; Luo ZZ; Xu QH; Zhou XY; Cao JN; Hong XN; Li XQ
Front Oncol; 2020; 10():803. PubMed ID: 32582543
[TBL] [Abstract][Full Text] [Related]
9. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
10. Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining.
Reinke S; Richter J; Fend F; Feller A; Hansmann ML; Hüttl K; Oschlies I; Ott G; Möller P; Rosenwald A; Stein H; Altenbuchinger M; Spang R; Klapper W
Virchows Arch; 2018 Sep; 473(3):341-349. PubMed ID: 29730836
[TBL] [Abstract][Full Text] [Related]
11. Classifying DLBCL according cell of origin using Hans algorithm and its association with clinicopathological parameters: A single centre experience.
Wn Najmiyah WAW; Azlan H; Faezahtul AH
Med J Malaysia; 2020 Mar; 75(2):98-102. PubMed ID: 32281588
[TBL] [Abstract][Full Text] [Related]
12. Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL.
Perfecto-Avalos Y; Garcia-Gonzalez A; Hernandez-Reynoso A; Sánchez-Ante G; Ortiz-Hidalgo C; Scott SP; Fuentes-Aguilar RQ; Diaz-Dominguez R; León-Martínez G; Velasco-Vales V; Cárdenas-Escudero MA; Hernández-Hernández JA; Santos A; Borbolla-Escoboza JR; Villela L
J Transl Med; 2019 Jun; 17(1):198. PubMed ID: 31185999
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay.
Crotty R; Hu K; Stevenson K; Pontius MY; Sohani AR; Ryan RJH; Rueckert E; Brauer HA; Hudson B; Berlin AM; Rodenbaugh M; Licon A; Haimes J; Iafrate AJ; Nardi V; Louissaint A
Am J Clin Pathol; 2021 Apr; 155(5):748-754. PubMed ID: 33258912
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
[TBL] [Abstract][Full Text] [Related]
16. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
Abdulla M; Hollander P; Pandzic T; Mansouri L; Ednersson SB; Andersson PO; Hultdin M; Fors M; Erlanson M; Degerman S; Petersen HM; Asmar F; Grønbaek K; Enblad G; Cavelier L; Rosenquist R; Amini RM
Am J Hematol; 2020 Jan; 95(1):57-67. PubMed ID: 31659781
[TBL] [Abstract][Full Text] [Related]
17. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
18. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland.
Reber R; Banz Y; Garamvölgyi E; Perren A; Novak U
Swiss Med Wkly; 2013; 143():w13748. PubMed ID: 23740154
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic evaluation of subgroups of diffuse large B cell lymphoma by immunohistochemistry.
Naz E; Mirza T; Danish F
Asian Pac J Cancer Prev; 2011; 12(12):3335-9. PubMed ID: 22471476
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma: Comprehension of cell-of-origin subtypes.
Rao S; Epari S; Shet TM; Gujral S; Jain H; Bagal B; Senagar M; Shetty P; Moiyadi A; Goda JS; Gupta T
Indian J Pathol Microbiol; 2023; 66(3):549-555. PubMed ID: 37530337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]